Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5422
Abstract: The purpose of this prospective, randomized study was to investigate the effectiveness and safety of the ixazomib+cyclophosphamide+dexamethasone (ICd) and ixazomib+dexamethasone (Id) regimens in newly diagnosed multiple myeloma (NDMM) who were elderly and frail and to…
read more here.
Keywords:
cyclophosphamide dexamethasone;
ixazomib cyclophosphamide;
newly diagnosed;
ixazomib dexamethasone ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007781
Abstract: Key Points Ixazomib, cyclophosphamide, and dexamethasone combination achieved hematologic response in 63% of newly diagnosed AL amyloidosis patients. The regimen is characterized with a favorable adverse event profile and should be explored in other combinations.
read more here.
Keywords:
cyclophosphamide dexamethasone;
trial ixazomib;
ixazomib cyclophosphamide;
phase trial ... See more keywords